BA
ALXN

Bristlecone Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Bristlecone Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-250
Closed -$35K – 273
2017
Q3 		$35K Buy
+250
New +$34K 0.01% 215

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bristlecone Advisors's ALXN Position: Q4 2017 in Review

Bristlecone Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 250 shares — an estimated $35K sold.

Bristlecone Advisors first reported a position in ALXN in Q3 2017 and held it in 1 quarter. The position peaked at $35K in Q3 2017. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Bristlecone Advisors reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Bristlecone Advisors sold 250 Alexion Pharmaceuticals shares in Q4 2017, an estimated $35K.
  • Bristlecone Advisors first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Bristlecone Advisors's Alexion Pharmaceuticals position peaked at $35K in Q3 2017.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Bristlecone Advisors's 13F filing for Q4 2017, filed 30 Jan 2018.